Table 4.

Univariate analysis: correlation between HR-pQCT measures and demographic and clinical variables (continuous variables). Results are expressed as correlation coefficient (r).

VariablesGeometryvBMDMicroarchitectureBiomechanical Properties
Total AreaCortical AreaTrabecular AreaCSAD100DcompDtrabDmetaDinnCt.ThBV/TVTb.NTb.ThTb.SpStiffnessEstimated Failure LoadApparent Modulus
Age−0.12−0.14−0.08−0.16−0.18−0.19−0.28*−0.29−0.68−0.12−0.28*−0.24*−0.2**0.26−0.32**−0.31**−0.22
Body height0.46**0.170.42**0.45**−0.0800.120.120.11−0.030.120.060.1−0.080.180.16−0.11
Body weight0.32**0.33**0.24*0.26*0.060.100.110.090.130.180.120.160.05−0.150.26*0.27*0.08
Body mass index0.10.210.040.060.040.050.030.010.050.150.040.11−0.01−0.090.130.140.07
Disease duration−0.05−0.02−0.060.020.08−0.060.090.130.070.010.10.040.14−0.040.110.090.06
SLEDAI0.24*0.060.23*0.21−0.04−0.080.180.180.19−0.060.180.220.08−0.220.040.05−0.07
SDI−0.16−0.32**−0.08−0.05−0.27*−0.30**−0.28**−0.28*−0.28*−0.28**−0.28**−0.25*−0.24*0.27*−0.27*−0.28*−0.22
25(OH)D0.1100.10.2−0.06−0.130.01−0.040.03−0.0700.010.01−0.02−0.11−0.05−0.16
Duration of GC use0.03−0.150.050.08−0.1−0.1800.04−0.02−0.14000.030.01−0.05−0.06−0.10
Average GC dose−0.09−0.04−0.07−0.0600.03−0.03−0.05−0.010.02−0.03−0.01−0.040.02−0.09−0.05−0.07
Cumulative GC dose−0.01−0.17−0.020.07−0.06−0.150.070.090.06−0.110.070.120.05−0.10−0.13−0.11−0.15
  • * p < 0.05.

  • ** p < 0.01; HR-pQCT: high-resolution peripheral quantitative computed tomography; SLEDAI: Systemic Lupus Erythematosus Disase Activity Index; SDI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; GC: glucocorticoid; CSA: cross-sectional area; vBMD: volumetric bone mineral density; D100: average bone density; Dcomp: cortical bone density; Dtrab: trabecular bone density; Dmeta: metatrabecular bone density; Dinn: inner trabecular bone density; Ct.Th: cortical thickness; BV/TV: trabecular bone volume/tissue volume; Tb.N: trabecular number; Tb.Th: trabecular thickness; Tb.Sp: trabecular separation.